These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25225241)

  • 41. Congestive heart failure in the elderly: comparison between reduced ejection fraction and preserved ejection fraction.
    Satomura H; Wada H; Sakakura K; Kubo N; Ikeda N; Sugawara Y; Ako J; Momomura S
    J Cardiol; 2012 Mar; 59(2):215-9. PubMed ID: 22266459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of heart failure with preserved ejection fraction in a population-based study.
    Bhatia RS; Tu JV; Lee DS; Austin PC; Fang J; Haouzi A; Gong Y; Liu PP
    N Engl J Med; 2006 Jul; 355(3):260-9. PubMed ID: 16855266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction.
    Adamson PB; Abraham WT; Bourge RC; Costanzo MR; Hasan A; Yadav C; Henderson J; Cowart P; Stevenson LW
    Circ Heart Fail; 2014 Nov; 7(6):935-44. PubMed ID: 25286913
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognosis in patients hospitalized with permanent and nonpermanent atrial fibrillation in heart failure.
    Taillandier S; Brunet Bernard A; Lallemand B; Simeon E; Pericart L; Clementy N; Babuty D; Fauchier L
    Am J Cardiol; 2014 Apr; 113(7):1189-95. PubMed ID: 24507167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER study (Identification of Patients With Heart Failure and PREserved Systolic Function: an epidemiological regional study).
    Magaña-Serrano JA; Almahmeed W; Gomez E; Al-Shamiri M; Adgar D; Sosner P; Herpin D;
    Am J Cardiol; 2011 Nov; 108(9):1289-96. PubMed ID: 22000627
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction.
    Adabag S; Rector TS; Anand IS; McMurray JJ; Zile M; Komajda M; McKelvie RS; Massie B; Carson PE
    Eur J Heart Fail; 2014 Nov; 16(11):1175-82. PubMed ID: 25302657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and Predictors of Early Heart Failure With Preserved Ejection Fraction in Patients With Paroxysmal Atrial Fibrillation.
    Meluzin J; Starek Z; Kulik T; Jez J; Lehar F; Wolf J; Dusek L; Leinveber P; Novak M
    J Card Fail; 2017 Jul; 23(7):558-562. PubMed ID: 28408305
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathophysiology of Atrial Fibrillation and Heart Failure: Dangerous Interactions.
    Sugumar H; Nanayakkara S; Prabhu S; Voskoboinik A; Kaye DM; Ling LH; Kistler PM
    Cardiol Clin; 2019 May; 37(2):131-138. PubMed ID: 30926014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.
    Schwartzenberg S; Redfield MM; From AM; Sorajja P; Nishimura RA; Borlaug BA
    J Am Coll Cardiol; 2012 Jan; 59(5):442-51. PubMed ID: 22281246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort.
    Quiroz R; Doros G; Shaw P; Liang CS; Gauthier DF; Sam F
    Am J Cardiol; 2014 Feb; 113(4):691-6. PubMed ID: 24484862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comorbidities, Sociodemographic Factors, and Hospitalizations in Outpatients With Heart Failure and Preserved Ejection Fraction.
    Georgiopoulou VV; Velayati A; Burkman G; Li S; Farooq K; Samman-Tahhan A; Papadimitriou L; Butler J; Kalogeropoulos AP
    Am J Cardiol; 2018 May; 121(10):1207-1213. PubMed ID: 29525061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
    Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
    Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction.
    Alla F; Al-Hindi AY; Lee CR; Schwartz TA; Patterson JH; Adams KF
    Am Heart J; 2007 Jun; 153(6):1074-80. PubMed ID: 17540212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women.
    Hung CL; Hung TC; Liu CC; Wu YJ; Kuo JY; Hou CJ; Yeh HI
    Am J Cardiol; 2012 Oct; 110(7):993-1000. PubMed ID: 22728006
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure.
    Mountantonakis SE; Grau-Sepulveda MV; Bhatt DL; Hernandez AF; Peterson ED; Fonarow GC
    Circ Heart Fail; 2012 Mar; 5(2):191-201. PubMed ID: 22361078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
    Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
    Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic factors and predictors of in-hospital mortality of patients with heart failure with preserved left ventricular ejection fraction.
    Pérez de Isla L; Zamorano J; Hernández N; Contreras L; Rodrigo JL; Almería C; Aubele AL; Mataix L; Macaya C
    J Cardiovasc Med (Hagerstown); 2008 Oct; 9(10):1011-5. PubMed ID: 18799963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction.
    Eapen ZJ; Greiner MA; Fonarow GC; Yuan Z; Mills RM; Hernandez AF; Curtis LH
    Am Heart J; 2014 Mar; 167(3):369-375.e2. PubMed ID: 24576522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial.
    Hasenfuß G; Hayward C; Burkhoff D; Silvestry FE; McKenzie S; Gustafsson F; Malek F; Van der Heyden J; Lang I; Petrie MC; Cleland JG; Leon M; Kaye DM;
    Lancet; 2016 Mar; 387(10025):1298-304. PubMed ID: 27025436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.